{"schema_version":"secwatch.filing_event.v1","accession":"0001737287-22-000072","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2022-09-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.860348+00:00","generated_at":"2026-06-23T08:19:14.205517+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Servier discontinues CD19 development; Allogene may exercise ex-US license at added cost","bullets":["Servier sent discontinuation notice for CD19 products (UCART19, ALLO-501, ALLO-501A) per Servier Agreement.","Allogene can elect ex-US license; if exercised, milestone payments for ALLO-501A increase by €46M aggregate.","Allogene's right to recover 40% of development costs from Servier would cease upon exercise of ex-US option.","Servier requested Allogene exercise option within limited timeframe; Cellectis challenges sublicense rights, adding legal risk."],"urls":{"canonical":"https://secwatch.observer/filing/0001737287-22-000072","json":"https://secwatch.observer/filing/0001737287-22-000072.json","markdown":"https://secwatch.observer/filing/0001737287-22-000072.md","text":"https://secwatch.observer/filing/0001737287-22-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000173728722000072/0001737287-22-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000173728722000072/allo-20220915.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T08:19:14.205517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}